WO1999037750A1 - Procede et dispositif de lyse cellulaire - Google Patents
Procede et dispositif de lyse cellulaire Download PDFInfo
- Publication number
- WO1999037750A1 WO1999037750A1 PCT/FR1999/000105 FR9900105W WO9937750A1 WO 1999037750 A1 WO1999037750 A1 WO 1999037750A1 FR 9900105 W FR9900105 W FR 9900105W WO 9937750 A1 WO9937750 A1 WO 9937750A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pipe
- lysis
- agent
- flow
- meeting point
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 49
- 230000006037 cell lysis Effects 0.000 title claims abstract description 6
- 230000009089 cytolysis Effects 0.000 claims abstract description 70
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 68
- 239000000203 mixture Substances 0.000 claims abstract description 36
- 241000894006 Bacteria Species 0.000 claims abstract description 16
- 239000006166 lysate Substances 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 239000013612 plasmid Substances 0.000 claims description 35
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 20
- 230000001376 precipitating effect Effects 0.000 claims description 15
- 239000006285 cell suspension Substances 0.000 claims description 13
- 230000003472 neutralizing effect Effects 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 13
- 239000000725 suspension Substances 0.000 claims description 13
- 239000013592 cell lysate Substances 0.000 claims description 11
- 230000001413 cellular effect Effects 0.000 claims description 11
- 235000011056 potassium acetate Nutrition 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 6
- 238000000265 homogenisation Methods 0.000 claims description 6
- 238000011084 recovery Methods 0.000 claims description 6
- 239000001632 sodium acetate Substances 0.000 claims description 5
- 235000017281 sodium acetate Nutrition 0.000 claims description 5
- 239000000815 hypotonic solution Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000005086 pumping Methods 0.000 claims description 3
- 239000008240 homogeneous mixture Substances 0.000 claims description 2
- 230000005465 channeling Effects 0.000 claims 1
- 230000004907 flux Effects 0.000 abstract 2
- 230000001580 bacterial effect Effects 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 10
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 238000013019 agitation Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 5
- 239000000470 constituent Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000009434 installation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000002572 peristaltic effect Effects 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000013492 plasmid preparation Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000007966 viscous suspension Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
Definitions
- the present invention relates to a method and a device for lysis of bacteria or eukaryotic cells, as well as extraction and purification of nucleic acids, and in particular plasmids, from bacteria or eukaryotic cells containing these plasmids.
- plasmids of interest and in particular of plasmids into which a gene or a coding DNA sequence has been inserted, is carried out by multicopy of these plasmids in bacteria capable of producing a large number of these plasmids, and in particular in certain strains of Escherichia coli highly productive of plasmids and often already used in the laboratory or on an industrial scale.
- the alkaline lysis technique which uses an alkaline lysis agent such as a sodium hydroxide + SDS preparation (sodium dodecyl sulfate), followed by neutralization with an acid agent, such as potassium acetate.
- This neutralizing agent also has the effect of precipitating all of the bacterial constituents, including genomic DNA, the supernatant essentially containing plasmid DNA. The supernatant can then be separated from the precipitate by centrifugation or filtration (Birnboim Methods in Enzymology (1983) 100: 243).
- the alkaline lysis technique is particularly recommended for lysing bacteria; but it can just as easily be used to lyse eukaryotic cells.
- Such a method therefore implements a specific means, namely a static mixer, which replaces manual agitation of large volumes with continuous agitation over the entire length of the mixer.
- a static mixer which replaces manual agitation of large volumes with continuous agitation over the entire length of the mixer.
- the use of such a mixer in addition to requiring the purchase, maintenance and cleaning of the device, imposes a fixed period of contact with the lysis agent, with no practical possibility of controlling it or modulate it.
- the stirring maintained in the mixer even if it is preferable to the poorly controlled stirring of discontinuous volumes, can cause breaks in, or degradations of cellular constituents and in particular of nucleic acids.
- Another method also makes it possible to establish continuous lysis, but this time without using agitation means.
- This process consists of (i) preparing a mixture of a bacterial suspension and an agent, such as lysozyme, allowing this mixture to incubate for approximately one hour in order to weaken the bacterial wall, then (ii) passing a flow of this mixture inside a pipe heated to high temperature (70-100 ° C).
- high temperature 70-100 ° C
- the action of heat promotes lysis.
- the disadvantage of such a solution is that it requires heating means to 3 high temperatures and an adaptation of the temperature to the different special cases that may be encountered.
- the present invention proposes to remedy these drawbacks and to provide a cell lysis process, applicable in particular to the extraction and purification of nucleic acids such as plasmids from bacteria or eukaryotic cells, which is capable of '' be implemented without manual intervention and under extremely economical conditions.
- Another objective of the invention is to provide a method which makes it possible to control in an extremely precise manner the conditions and the duration of the lysis and of the extraction and this for all the cells present.
- Another objective is to provide a method making it possible to establish substantially homogeneous lysis conditions for a population of cells.
- Another objective is to provide a process capable of being implemented in a closed environment, free from contamination, which is an advantage for the pharmaceutical quality of the products sought, for example plasmids.
- Another objective is to obtain a reduction in the duration of the cell / lysis agent contact, which is necessary to complete the lysis.
- Another objective is to provide a device for implementing this method, a simple and inexpensive device.
- Another objective is to provide on an industrial scale, plasmid preparations with a high yield and appreciably improved compared to that of the preparations which can be obtained according to the methods of the prior art.
- the invention is based on the unexpected discovery that it is possible, by respecting a certain number of parameters, to ensure a homogeneous and controlled lysis of cells, and in particular of bacteria, by simple continuous mixing, in a usual pipe, of a suspension of cells with a lysis agent, despite the expected high viscosity, without using any of the means of the prior art such as a static mixer or high temperatures.
- the invention therefore relates to a cell lysis process in which a liquid mixture of cells and a lysis agent is produced continuously, and 4 immediately causes this mixture to flow under a constant flow, inside a pipeline, the flow rate of this flow being adapted, as a function of the diameter and the length of the pipeline, so as to obtain a cell lysate substantially homogeneous with the outlet of said pipe. Obtaining a homogeneous lysate results in a sharp drop in turbidity and the appearance of a mixture transparent to the eye.
- the pipeline has a small internal diameter so that the mixture forms almost instantly in a homogeneous manner, without the formation of separate liquid veins.
- This diameter can be determined experimentally. In general, a diameter of the order of 1 cm or preferably less meets this definition, and a diameter of between 2 and 8 mm is preferred.
- the diameter and the flow rate are elements of the process fixed in advance, it is just as possible to adapt the length of the pipe so as to obtain the desired effect. For example, for a given diameter and flow rate, it is enough to play on the length of the pipe, e.g., using a simple flexible pipe that is cut to the desired length.
- the minimum length of the pipeline from the meeting point of the cell suspension and the lysis agent, which is necessary to travel to reach the lysis state, can be easily determined by simple observation through a pipeline transparent, from the reduction in the turbidity of the mixture until the appearance of a lysate transparent to the eye.
- a pipe length of the order of 10 cm to a few meters is generally suitable.
- One of the advantages of the invention consists in the homogeneity of the mixture during lysis (the duration of lysis is substantially identical for all bacteria); which ultimately allows a homogeneous lysate to be obtained. This is achieved by the appropriate choice of the parameters of the invention (diameter, and length of pipe, flow rate), without having to use stirring or heating means.
- the mixture of cells and of lysis agent is produced by introducing, into the aforesaid pipeline, a flow of cells, for example of a 5 cell suspension, and a flow of a lysis agent solution, so that the flow of the flow of this mixture produces rapid homogenization, which is almost instantaneous, if using a reduced diameter pipeline.
- the lysis agent can be a chemical agent, for example an alkaline agent, such as a sodium hydroxide solution + SDS, preferably a 0.2 M NaOH / 1% SDS mixture. It can also be a hypotonic solution compared to the cellular environment, intended to cause osmotic shock. In the case where the bacteria are simply transferred to a hypotonic solution, they have been treated beforehand so that their wall is weakened, by an agent such as lysozyme. Treatment with an alkaline agent is particularly suitable for bacterial lysis, while treatment with a hypotonic solution is particularly suitable for lysis of eukaryotic cells.
- an alkaline lysis agent it is preferable to add to the lysate, a neutralizing agent. Indeed, the addition of this agent makes it possible to stop the degrading action linked to the alkaline agent, once a complete and homogeneous lysis has been obtained.
- another advantage of the invention lies in exercising control over the period during which the cells are subjected to strongly alkaline pH conditions. This makes it possible to very easily implement the optimal duration conditions resulting in a total and homogeneous lysis while avoiding prolonging the action of the alkaline agent beyond the time necessary and sufficient to complete the lysis in order to avoid any action. deleterious in particular on DNA.
- the neutralizing agent which is added to the lysate arriving at the end of the pipeline may preferably be sodium or potassium acetate, for example 3 M potassium acetate. It is advantageously chosen to so as to obtain a final pH close to 5.5 thanks to the addition of HCI 12N.
- the aim pursued in fine consists eg in extracting plasmids
- a precipitating agent sodium or potassium acetate can be used, for example 6
- potassium acetate 3 M It is advantageously chosen so as to obtain a final pH close to 5.5 thanks to the addition of HCl 12N.
- a precipitation agent such as sodium or potassium acetate also serves as a neutralizing agent, when the alkaline lysis technique is used.
- the subject of the invention is also a method of extraction and / or purification of nucleic acids, in particular of plasmids, from a cell suspension, in which (i) the lysis method according to the invention in order to obtain a cell lysate and, continuously with the lysis process, (i) the cell lysate is treated with a precipitating and / or neutralizing agent, in order to obtain a preparation comprising a supernatant containing the plasmid DNA and a precipitated or flocculated phase containing the majority of cellular elements including genomic DNA.
- a continuous mixture of a cell suspension and a liquid preparation (solution) of a lysis agent is produced, at a first determined meeting point, starting from from which a constant flow of said mixture is established in a pipe, in order to homogenize the mixture of the suspension and of the lysis agent, (ii) this mixture is maintained in this constant flow for a determined duration, and at the end of this duration (iii) adding, at a second determined meeting point, a solution of a precipitating agent; said duration being determined by the distance separating said first and second meeting points and by the speed of movement of the mixture (or linear flow) over this distance.
- This plasmid extraction process can advantageously be implemented in the following way: (i) a flow of the cell suspension is established in a first channel;
- a flow of the preparation obtained at the second meeting point is established, by mixing the cell lysate with the precipitation agent; and (vi) a preparation comprising a supernatant containing the plasmid DNA and a precipitated or flocculated phase containing the majority of the cellular elements including the genomic DNA is recovered at the outlet of the fifth channel.
- step (vi) of recovery it is also possible to proceed, in any manner, with the separation of the supernatant from the precipitated or flocculated phase, preferably continuously from step (vi) of recovery.
- the time required to obtain a complete and homogeneous lysis taking into account the usual proportions of suspension and of lysis agent, can be very substantially reduced and even less than one or more minutes, for example 5 min and even reduced to such low values. one or two seconds, contrasting with the ten minutes required in the prior art.
- the proportion of flow rates, and therefore of mixed volumes preferably meets the following definitions: - bacterial suspension / lysis agent (for example sodium hydroxide mixture +
- SDS between 1/4 and 3/4, and preferably of the order of 1/2
- alkaline lysis agent / neutralizing acid agent preferably potassium acetate: between 1 and 2 and preferably of the order of 1, 3.
- the concentration of the bacterial suspension is of the order of 170 grams (by wet weight of bacteria) / liter of a conventional buffer (for example Tris EDTA) + glucose.
- a conventional buffer for example Tris EDTA
- the cell suspension is stored at low temperature and directed at this same temperature in the pipe towards the meeting point with the lysis agent, this temperature preferably being of the order of 4 ° C.
- the lysis agent can be maintained and transported at ambient temperature and the precipitating and / or neutralizing agent is preferably maintained at low temperature, such as 4 ° C. 9
- the invention also relates to a device for implementing this process, characterized in that it comprises, from a source of cell suspension, such as a reservoir, a pipe allowing the establishment of a flow of cell suspension, from a source of a lysis agent such as a reservoir, a second line allowing the establishment of a flow of the lysis agent, said first and second lines leading to a first meeting point into which they open into one another, - a third pipe of small diameter and of determined length extending from said first meeting point, and means, such as pumping means, for the establishment of flows in said pipes; the length, the diameter and the flow rate in said third pipe being adapted so as to obtain a substantially homogeneous mixture resulting in a substantially homogeneous lysate.
- the device may also comprise: from a source of neutralizing and / or precipitating agent, such as a reservoir, a fourth pipe leading to a second meeting point at the end of said third pipe so that the pipes open into one another, said third pipe having a length determined by the distance between said first meeting point and said second meeting point; from said second meeting point, a fifth small diameter pipe leading to recovery and / or separation means; and and means, such as pumping means, for establishing the flows in said fourth and fifth pipes.
- a source of neutralizing and / or precipitating agent such as a reservoir
- a fourth pipe leading to a second meeting point at the end of said third pipe so that the pipes open into one another said third pipe having a length determined by the distance between said first meeting point and said second meeting point
- a fifth small diameter pipe leading to recovery and / or separation means and and means, such as pumping means, for establishing the flows in said fourth and fifth pipes.
- all the pipes have small diameters as defined above.
- the small diameters of said pipes can be identical or different.
- the differences in diameter between pipes can be determined by the flow establishment means. 10
- the means for establishing the flows can advantageously be pumps, preferably one or more peristaltic pumps making it possible to establish, in the various pipes, the flow rates, and therefore, taking into account the diameters of the pipes, the desired speeds.
- the same pump for example, a peristaltic pump with several parallel channels, so as to ensure, even in the event of untimely variation of the pump flow rate , a constant proportionality between said flows.
- the arrangement of the pipes according to the invention can be split, tripled or multiplied, preferably with flow establishment means, such as a pump, single or more pumps joined together so as to maintain, in all circumstances, a constant proportionality of the flows in each of the installations.
- the outlet from one pipe to the other at a meeting point can be made at any angle. Generally it is preferred that one of the pipes opens substantially perpendicularly into the other but it is also possible to tilt the axes of the outlets.
- the device according to the invention may include means for establishing and controlling temperatures so as to maintain the sources at the required temperatures.
- the installation can be arranged so that the low temperature is maintained not only in the source but also in the first pipeline to the point where lysis begins.
- An installation according to the invention makes it possible, for example, to treat a volume of bacterial suspension of the order of 1 to 5 liters per hour. 1 1
- the mixture obtained downstream of the first meeting point exhibits great homogeneity throughout the duration of the treatment, as does the neutralized mixture downstream of the second meeting point, so that the separation means making it possible to separate, on the one hand , the plasmids remaining in solution, and, on the other hand, the other precipitated or flocculated cellular elements, work under constant conditions and contribute to the excellent reproducibility of the final purified plasmid preparation.
- the bacterial suspension to be lysed is a suspension originating from a culture of an E. coli strain in which a plasmid such as the plasmid pUC18 in Tris EDTA buffer has been multiplied with a bacterial concentration of the order of 200 g (weight wet) per liter.
- the sodium hydroxide-SDS mixture is a 0.2 M NaOH / 1% SDS mixture.
- the potassium acetate solution used as a neutralizing agent is 3 M; pH 5.5.
- the device shown in the figure comprises a first container 1 containing the bacterial suspension.
- a first container 1 containing the bacterial suspension.
- To this container are associated means for maintaining a temperature of the order of + 4 ° C. (not shown) and stirring means 2 making it possible to maintain the homogeneity of the suspension.
- From the source 1 extends a flexible silicone pipe having an internal diameter of 2.06 mm and forming the first section of pipe 3.
- the sodium hydroxide-SDS mixture is contained in a reservoir 4 from which extends a second pipe, 5 with an internal diameter of 3.17 mm and made of the same flexible material.
- the pipe 3 opens perpendicularly into the pipe 5 so that at this location a mixture forms, causing rapid lysis of the bacteria.
- From point 6 extends a third section of 12 pipe, 7 to point 8 forming the second meeting point, the length of pipe 7 being 0.8 meters.
- This pipe 7 has an internal diameter of 7 mm (modular).
- the potassium acetate solution is contained in a reservoir 9 from which extends a fourth pipe 10 also made of flexible material having an internal diameter of 2.79 mm opening into the pipe 7 at the meeting point 8, also perpendicular to line 7.
- the container 9 is also associated with means for maintaining at low temperature + 4 ° C. From the second meeting point 8 extends a fifth pipe 11, formed subsequently by the pipe 7, this pipe 11 leading to a recovery tank 12.
- diameters of the three pipes 3, 5 and 10 are in ratios such that the proportions of the internal sections of the pipes ensure, for the same speed of circulation of the liquids, the desired mixing proportions.
- the flow rates thus obtained are respectively 160 ml / min in 7 and 244 ml / min in 11.
- the bacteria are subjected to the action of the sodium hydroxide + SDS mixture throughout the duration of the path of the liquid in the pipe 7, between points 6 and 8. This duration, in the example chosen, is 15 sec.
- a lysed preparation comprising two phases, namely a clear soluble phase containing the plasmids, substantially free of cellular element and an insoluble upper phase containing substantially the cellular elements. 13
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU20604/99A AU756179B2 (en) | 1998-01-21 | 1999-01-20 | Method and device for cell lysis |
EP99900963A EP1049766A1 (fr) | 1998-01-21 | 1999-01-20 | Procede et dispositif de lyse cellulaire |
JP2000528658A JP2002500878A (ja) | 1998-01-21 | 1999-01-20 | 細胞溶解のための方法および装置 |
CA002319021A CA2319021A1 (fr) | 1998-01-21 | 1999-01-20 | Procede et dispositif de lyse cellulaire |
NZ505865A NZ505865A (en) | 1998-01-21 | 1999-01-20 | Method for cell lysis continuously producing a mixture of nucleated cells and lysing agent , the mixture flows in a steady stream through a tube having a diameter of 1cm or less |
US09/600,664 US6664049B1 (en) | 1999-01-20 | 1999-01-20 | Method and device for cell lysis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9800815A FR2773818B1 (fr) | 1998-01-21 | 1998-01-21 | Procede et dispositif de lyse de bacteries |
FR98/00815 | 1998-01-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999037750A1 true WO1999037750A1 (fr) | 1999-07-29 |
Family
ID=9522178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1999/000105 WO1999037750A1 (fr) | 1998-01-21 | 1999-01-20 | Procede et dispositif de lyse cellulaire |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1049766A1 (fr) |
JP (1) | JP2002500878A (fr) |
AU (1) | AU756179B2 (fr) |
CA (1) | CA2319021A1 (fr) |
FR (1) | FR2773818B1 (fr) |
NZ (1) | NZ505865A (fr) |
WO (1) | WO1999037750A1 (fr) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001025482A1 (fr) * | 1999-10-02 | 2001-04-12 | Bioneer Corporation | Appareil de purification d'adn automatique |
US6664049B1 (en) | 1999-01-20 | 2003-12-16 | Aventis Pasteur S.A. | Method and device for cell lysis |
KR100470803B1 (ko) * | 2002-09-25 | 2005-03-10 | 대한민국(관리부서:국립수산과학원) | 형질전환 어류의 피씨알 분석을 위한 신속한 디앤에이 추출 방법 |
WO2005026331A3 (fr) * | 2003-09-17 | 2005-11-17 | Gencell Sas | Procede de preparation d'adn plasmide de qualite pharmaceutique |
WO2006029908A1 (fr) * | 2004-09-17 | 2006-03-23 | Centelion | Preparations liquides stables d'adn plasmidique |
EP2088196A1 (fr) | 2008-02-08 | 2009-08-12 | Boehringer Ingelheim RCV GmbH & Co KG | Procédés et dispositifs pour la production de biomolécules |
JP2010500042A (ja) * | 2006-08-15 | 2010-01-07 | ビーエーエスエフ ソシエタス・ヨーロピア | 産生細胞からのタンパク質単離方法 |
US8501402B2 (en) | 2003-03-24 | 2013-08-06 | Boehringer Ingelheim Rcv Gmbh & Co Kg | Methods and devices for producing biomolecules |
EP3594338A1 (fr) | 2018-07-12 | 2020-01-15 | Kaneka Eurogentec SA | Procédé et appareil pour la purification de séquences d'acides nucléiques extra-chromosomiques |
CN111979109A (zh) * | 2020-09-01 | 2020-11-24 | 深圳普瑞金生物药业有限公司 | 质粒载体连续裂解装置 |
WO2021198281A1 (fr) * | 2020-03-31 | 2021-10-07 | Richter-Helm Biologics Gmbh & Co. Kg | Procédés de production d'adn plasmidique |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0509490A (pt) * | 2004-04-19 | 2007-09-11 | Centelion | método de purificação de plasmìdeo dna |
DE102004052254A1 (de) * | 2004-05-03 | 2005-12-01 | Plasmid Factory Gmbh & Co. Kg | Verfahren zum Aufschluss von Zellen und zur Abtrennung von Zellbestandteilen |
DK2102354T3 (da) * | 2007-01-12 | 2017-11-27 | Dow Global Technologies Llc | Apparater og fremgangsmåder til osmotisk shockering af celler |
EP2678429B1 (fr) * | 2011-02-21 | 2018-04-18 | Rheonix, Inc. | Procédé de purification d'acides nucléiques basé sur un dispositif microfluidique |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4294824A (en) * | 1975-08-05 | 1981-10-13 | The Union International Company, Ltd. | Extracts of the hemopoietic system |
DE4028771A1 (de) * | 1989-09-14 | 1991-02-21 | Bert Sobolewski | Verfahren zur trennung von parasiten, organellen o. dgl. von den sie umgebenden biologischen membranen |
US5096818A (en) * | 1990-06-04 | 1992-03-17 | Autogen Instruments, Inc. | Nucleic acid separation method |
WO1996002658A1 (fr) * | 1994-07-15 | 1996-02-01 | Merck & Co., Inc. | Procede de purification plasmidique a grande echelle |
WO1997023601A1 (fr) * | 1995-12-21 | 1997-07-03 | Genzyme Corporation | Procede de lyse de cellules |
-
1998
- 1998-01-21 FR FR9800815A patent/FR2773818B1/fr not_active Expired - Fee Related
-
1999
- 1999-01-20 CA CA002319021A patent/CA2319021A1/fr not_active Abandoned
- 1999-01-20 NZ NZ505865A patent/NZ505865A/xx unknown
- 1999-01-20 JP JP2000528658A patent/JP2002500878A/ja not_active Withdrawn
- 1999-01-20 WO PCT/FR1999/000105 patent/WO1999037750A1/fr not_active Application Discontinuation
- 1999-01-20 EP EP99900963A patent/EP1049766A1/fr not_active Withdrawn
- 1999-01-20 AU AU20604/99A patent/AU756179B2/en not_active Ceased
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4294824A (en) * | 1975-08-05 | 1981-10-13 | The Union International Company, Ltd. | Extracts of the hemopoietic system |
DE4028771A1 (de) * | 1989-09-14 | 1991-02-21 | Bert Sobolewski | Verfahren zur trennung von parasiten, organellen o. dgl. von den sie umgebenden biologischen membranen |
US5096818A (en) * | 1990-06-04 | 1992-03-17 | Autogen Instruments, Inc. | Nucleic acid separation method |
WO1996002658A1 (fr) * | 1994-07-15 | 1996-02-01 | Merck & Co., Inc. | Procede de purification plasmidique a grande echelle |
WO1997023601A1 (fr) * | 1995-12-21 | 1997-07-03 | Genzyme Corporation | Procede de lyse de cellules |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6664049B1 (en) | 1999-01-20 | 2003-12-16 | Aventis Pasteur S.A. | Method and device for cell lysis |
WO2001025482A1 (fr) * | 1999-10-02 | 2001-04-12 | Bioneer Corporation | Appareil de purification d'adn automatique |
KR100470803B1 (ko) * | 2002-09-25 | 2005-03-10 | 대한민국(관리부서:국립수산과학원) | 형질전환 어류의 피씨알 분석을 위한 신속한 디앤에이 추출 방법 |
US8501402B2 (en) | 2003-03-24 | 2013-08-06 | Boehringer Ingelheim Rcv Gmbh & Co Kg | Methods and devices for producing biomolecules |
EP1664277B1 (fr) * | 2003-09-17 | 2011-11-09 | Aventis Pharma S.A. | Procede de preparation d'adn plasmide de qualite pharmaceutique |
WO2005026331A3 (fr) * | 2003-09-17 | 2005-11-17 | Gencell Sas | Procede de preparation d'adn plasmide de qualite pharmaceutique |
EA009447B1 (ru) * | 2003-09-17 | 2007-12-28 | Сентельон | Способ получения плазмидной днк фармацевтического качества |
CN1882682B (zh) * | 2003-09-17 | 2010-06-16 | 森特利昂公司 | 药物级别质粒dna的制备方法 |
WO2006029908A1 (fr) * | 2004-09-17 | 2006-03-23 | Centelion | Preparations liquides stables d'adn plasmidique |
EA011554B1 (ru) * | 2004-09-17 | 2009-04-28 | Сентелион | Стабильные жидкие композиции плазмидной днк |
JP2010500042A (ja) * | 2006-08-15 | 2010-01-07 | ビーエーエスエフ ソシエタス・ヨーロピア | 産生細胞からのタンパク質単離方法 |
EP2088196A1 (fr) | 2008-02-08 | 2009-08-12 | Boehringer Ingelheim RCV GmbH & Co KG | Procédés et dispositifs pour la production de biomolécules |
EP3594338A1 (fr) | 2018-07-12 | 2020-01-15 | Kaneka Eurogentec SA | Procédé et appareil pour la purification de séquences d'acides nucléiques extra-chromosomiques |
WO2020011641A1 (fr) | 2018-07-12 | 2020-01-16 | Kaneka Eurogentec S.A. | Procédé et appareil pour la purification de séquences d'acides nucléiques extra-chromosomiques |
EP4116417A1 (fr) | 2018-07-12 | 2023-01-11 | Kaneka Eurogentec SA | Procédé et appareil pour la purification de séquences d'acides nucléiques extra-chromosomiques |
US12060552B2 (en) | 2018-07-12 | 2024-08-13 | Kaneka Eurogentec S.A. | Method and apparatus for the purification of extra-chromosomal nucleic acids sequences |
WO2021198281A1 (fr) * | 2020-03-31 | 2021-10-07 | Richter-Helm Biologics Gmbh & Co. Kg | Procédés de production d'adn plasmidique |
CN111979109A (zh) * | 2020-09-01 | 2020-11-24 | 深圳普瑞金生物药业有限公司 | 质粒载体连续裂解装置 |
Also Published As
Publication number | Publication date |
---|---|
EP1049766A1 (fr) | 2000-11-08 |
AU2060499A (en) | 1999-08-09 |
NZ505865A (en) | 2002-12-20 |
FR2773818A1 (fr) | 1999-07-23 |
AU756179B2 (en) | 2003-01-09 |
CA2319021A1 (fr) | 1999-07-29 |
JP2002500878A (ja) | 2002-01-15 |
FR2773818B1 (fr) | 2000-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999037750A1 (fr) | Procede et dispositif de lyse cellulaire | |
EP2139818A2 (fr) | Procede et dispositif d'epuration d' effluents liquides | |
US6664049B1 (en) | Method and device for cell lysis | |
CA2491164A1 (fr) | Appareil liposomal et procedes de fabrication | |
WO2010070228A1 (fr) | Procede d'ammonolyse de l'acide 11-bromoundecanoïque | |
CA2212446C (fr) | Procede de lyse de cellules | |
JP2005538717A (ja) | 核酸のプレパラティブスケールの精製のための装置および方法 | |
FR2777293A1 (fr) | Procede d'electro-separation d'un echantillon biologique et dispositif de mise en oeuvre | |
CA2249465A1 (fr) | Purification d'adn plasmidique de qualite pharmaceutique | |
WO2010081903A1 (fr) | Dispositif d'enrobage avec un materiau polymere floculant a l'etat liquide de grains de ballast utilises pour le traitement de l'eau par floculation lestee, et installation correspondante | |
CA2579342A1 (fr) | Installation de traitement d'effluents, et procede de clarification et de filtration utilisant cette installation | |
EP0387708B1 (fr) | Procédé de réduction de la teneur en cholestérol et en acides gras libres d'une matière grasse d'origine animale et matière grasse ainsi obtenue | |
EP1235635B1 (fr) | Procede de filtration membranaire de liquides et dispositif de mise en oeuvre dudit procede | |
EP1819759B1 (fr) | Procede et dispositif de fabrication de billes ou de ballons en mousse polymere | |
EP2633905A1 (fr) | Procédé et dispositif pour la réalisation d'une réaction chimique polyphasée | |
BE1029550B1 (fr) | Extraction plasmidique automatisée | |
BE1028063B1 (fr) | Methode de purification d'acide hyaluronique | |
FR2990212A1 (fr) | Procede de recuperation d'hydrocarbures a partir d'une boue et dispositif mettant en oeuvre un tel procede | |
WO2020136212A1 (fr) | Procede et dispositif d'amelioration de la biodegradabilite d'une boue | |
BE1030362B1 (fr) | Extraction périplasmique automatisée | |
WO2018065699A1 (fr) | Appareil de regulation de pression d'injection pour la recuperation assistee du petrole par polymere | |
FR3154122A1 (fr) | Bioréacteur pour la production de biomolécules | |
BE1030204A1 (fr) | Méthodes et systèmes de coiffage de molécules d’acide nucléique | |
FR2598429A1 (fr) | Procede et dispositif pour le dessalage d'une charge hydrocarbonee liquide, notamment de petrole brut | |
TavakoliNaeini | Large Scale Production, Purification, and Modification of Chitosan-Based Complexes for Gene Therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 20604/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 505865 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2319021 Country of ref document: CA Ref country code: CA Ref document number: 2319021 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999900963 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999900963 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09600664 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 20604/99 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999900963 Country of ref document: EP |